Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.
$RNA
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2026 | $25.00 | Overweight | Wells Fargo |
| 9/17/2025 | $62.00 | Buy | Roth Capital |
| 7/10/2025 | $55.00 | Buy | Goldman |
| 6/24/2025 | $50.00 | Outperform | Bernstein |
| 6/17/2025 | $55.00 | Outperform | Wolfe Research |
| 6/11/2025 | $65.00 | Strong Buy | Raymond James |
| 3/13/2025 | $70.00 | Buy | Citigroup |
| 3/12/2025 | $72.00 | Outperform | BMO Capital Markets |
Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00
Roth Capital initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $62.00
Goldman resumed coverage of Avidity Biosciences with a rating of Buy and set a new price target of $55.00
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathl
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida. 2026 MDA Clinical & Scientific Congress PresentationsOral Presentation: Del-zota Treatment is As
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends to reconvene the Special Meeting on February 26, 2026, at 10:00 a.m., Eastern time. Stockholders who have already registered for the Special Meeting will not nee
8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
DEFA14A - Avidity Biosciences, Inc. (0001599901) (Filer)
10-K - Avidity Biosciences, Inc. (0001599901) (Filer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipelineExpected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, and bolsters mid-single digit long-term growthAs part of the agreement, Avidity will separate its early-stage precision cardiology programs into a new company ("SpinCo") prior to closingCo
Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)